BioMarin Pharmaceutical (BMRN) AI Stock Analysis

• Market Cap: $10.99B
• Dividend Yield: N/A
• Average Volume (3M): 2.01M
• Price to Earnings (P/E): 21.0
• Beta (1Y): 0.43
• Revenue Growth: 17.99%
• EPS Growth: 152.10%
• Country: US
• Employees: 3,040
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): 0.95
• Shares Outstanding: 191,775,670
• 10 Day Avg. Volume: 1,822,934
• 30 Day Avg. Volume: 2,011,637
• PEG Ratio: 0.93
• Price to Book (P/B): 1.87
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 17.52
• Enterprise Value/Market Cap: 0.95
• Enterprise Value/Revenue: 0.94
• Enterprise Value/Gross Profit: 4.49
• Enterprise Value/Ebitda: 4.49
• 1Y Price Target: $96.11
• Price Target Upside: 62.35% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 20

• Rating: 77 Outperform
• Price Target: $67.00 ▲(13.18%Upside)

BioMarin Pharmaceutical demonstrates a strong overall performance, driven by robust financials and strategic acquisitions. The company's focus on innovation and global diversification supports its growth potential, although its moderate valuation and absence of a dividend yield may temper some investor enthusiasm.

Positive Factors

Growth Potential

BioMarin's recent deal with Inozyme is seen as a capital-efficient way to scale the ERT business, supporting the company's potential for diversification and growth.

Revenue Projection

Further out, there is under-appreciated revenue potential, with net product revenues modeled at $4.03B in FY27, aligning with company guidance but above consensus estimates.

Valuation

BioMarin shares are significantly undervalued with little investor credit given for the pipeline, especially the commercial opportunity with Voxzogo.

Negative Factors

Competition

BMRN's key product, Voxzogo for achondroplasia faces potential new competition from Ascendis' TranCon CNP, which may lead to a loss of market share.

Market Share Risk

A quarter of Voxzogo-treated patients could switch to TransCon CNP, which poses a risk to maintaining Voxzogo's patient base.

Product Differentiation

The KOL thought that many parents and patients would prefer a once-weekly option over Voxzogo's daily dosing, indicating a potential challenge for maintaining market share.

BioMarin Pharmaceutical Business Overview & Revenue Model

Company Description

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.

How the Company Makes Money

BioMarin Pharmaceutical makes money primarily through the sale of its proprietary biopharmaceutical products. The company's revenue streams are driven by the commercialization of its approved therapies, which are often high-priced due to their specificity and effectiveness in treating rare diseases. Key revenue-generating products include Vimizim, Naglazyme, and Palynziq, among others. Additionally, BioMarin invests in research and development to expand its product pipeline, which could lead to future revenue opportunities. The company also engages in strategic partnerships and collaborations with other pharmaceutical firms and research institutions to enhance its product offerings and market reach, contributing to its earnings.

BioMarin Pharmaceutical Financial Statement Overview

Summary

BioMarin Pharmaceutical demonstrates strong financial performance with robust revenue growth and improved profit margins. The company's balance sheet is solid with low leverage, and cash flow management is effective, highlighting operational efficiency.

Income Statement

BioMarin Pharmaceutical has demonstrated a robust financial performance with strong revenue growth, rising from $2.09 billion in 2022 to $2.93 billion TTM (Trailing-Twelve-Months). The gross profit margin remains healthy, supported by efficient cost management. The net profit margin and EBIT margins have also shown significant improvement, indicating enhanced profitability. The consistent EBITDA margin growth highlights operational efficiency gains.

Balance Sheet

The company's balance sheet is strong, characterized by a low debt-to-equity ratio, suggesting prudent financial leverage. The equity ratio is impressive, indicating a high level of asset financing through equity. The return on equity has improved substantially, showcasing the company's ability to generate profits from shareholders' investments. However, the company should continue monitoring its debt levels to maintain financial flexibility.

Cash Flow

BioMarin Pharmaceutical has demonstrated strong cash flow dynamics with significant growth in free cash flow, reflecting effective capital expenditure management. The operating cash flow to net income ratio is favorable, indicating robust cash generation capabilities. The improved free cash flow to net income ratio further underscores the company's solid cash flow management.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.85B	2.42B	2.10B	1.85B	1.86B
Gross Profit	2.27B	1.84B	1.61B	1.38B	1.34B
EBITDA	650.86M	310.28M	267.51M	48.03M	-5.85M
Net Income	426.86M	167.65M	141.56M	-64.08M	854.03M
Balance Sheet
Total Assets	6.99B	6.84B	6.38B	6.00B	5.85B
Cash, Cash Equivalents and Short-Term Investments	1.14B	1.07B	1.29B	1.01B	1.07B
Total Debt	602.71M	1.10B	1.08B	1.08B	1.08B
Total Liabilities	1.33B	1.89B	1.77B	1.73B	1.74B
Stockholders Equity	5.66B	4.95B	4.60B	4.27B	4.11B
Cash Flow
Free Cash Flow	475.42M	51.65M	44.36M	185.31M	-52.15M
Operating Cash Flow	572.84M	159.26M	175.90M	304.54M	85.36M
Investing Cash Flow	136.49M	-111.24M	-20.03M	-366.31M	-53.62M
Financing Cash Flow	-526.45M	-18.73M	-18.65M	-48.00K	181.12M

BioMarin Pharmaceutical Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 59.20
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BMRN, the sentiment is Positive. The current price of 59.2 is above the 20-day moving average (MA) of 57.03, above the 50-day MA of 57.31, and below the 200-day MA of 63.86, indicating a neutral trend. The MACD of 0.30 indicates Negative momentum. The RSI at 57.64 is Neutral, neither overbought nor oversold. The STOCH value of 37.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BMRN.

BioMarin Pharmaceutical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EXEL	84 Outperform	$12.13B	20.08	30.22%	―	24.49%	244.87%
UTHR	78 Outperform	$13.17B	11.70	19.94%	―	19.85%	21.16%
BMRN	77 Outperform	$10.99B	20.99	9.64%	―	17.99%	152.10%
INCY	73 Outperform	$13.14B	208.48	0.47%	―	17.13%	-88.78%
GMAB	72 Outperform	$13.67B	12.18	22.69%	―	25.11%	46.46%
Sector *	58 Neutral	£4.74B	6.56	-62.36%	102.23%	34.03%	6.31%
ASND	52 Neutral	$9.99B	―	357.68%	―	10.69%	34.71%

BioMarin Pharmaceutical Corporate Events

BioMarin Pharmaceutical Approves Equity Plan Amendment

On May 20, 2025, BioMarin Pharmaceutical Inc. held its Annual Meeting of Stockholders, where stockholders approved an amendment to the 2017 Equity Incentive Plan, increasing the number of shares reserved for issuance by 8,000,000. This amendment, effective immediately, was previously approved by the Compensation Committee, indicating strong internal support for expanding equity incentives. Additionally, stockholders elected ten directors, ratified KPMG LLP as the independent registered public accounting firm, and approved executive compensation, reflecting continued confidence in the company’s leadership and strategic direction.

The most recent analyst rating on (BMRN) stock is a Buy with a $120.00 price target. To see the full list of analyst forecasts on BioMarin Pharmaceutical stock, see the BMRN Stock Forecast page.

BioMarin Acquires Inozyme Pharma for $270 Million

On May 16, 2025, BioMarin Pharmaceutical Inc. announced an agreement to acquire Inozyme Pharma, Inc. for approximately $270 million. This acquisition aims to enhance BioMarin’s enzyme therapy portfolio by adding INZ-701, a late-stage enzyme replacement therapy for ENPP1 Deficiency, a rare genetic condition. The transaction is expected to close in the third quarter of 2025, pending regulatory approval and other conditions. The acquisition is strategically significant for BioMarin, as it aligns with their commitment to advancing treatments for serious genetic conditions, potentially offering the first treatment for ENPP1 Deficiency. The first pivotal data readout for INZ-701 in children is anticipated in early 2026, with a potential launch in 2027, marking a significant step forward in addressing unmet medical needs.

The most recent analyst rating on (BMRN) stock is a Buy with a $120.00 price target. To see the full list of analyst forecasts on BioMarin Pharmaceutical stock, see the BMRN Stock Forecast page.